Santen Pharmaceutical Co Ltd is a renowned company known for its core values and corporate philosophy. Committed to improving ophthalmic healthcare, Santen focuses on integrity, innovation, and dedication to patients worldwide. The company prioritizes delivering effective and safe solutions, aiming to contribute to the well-being of patients and the global community. Santen Pharmaceutical Co Ltd values ethical business conduct, transparency, and sustainable practices. With a strong emphasis on research and development, Santen continuously strives to enhance existing treatments and develop advanced therapeutic options. Passionate about providing innovative solutions, Santen Pharmaceutical Co Ltd is dedicated to improving vision and quality of life for individuals affected by ocular diseases.

Santen Pharmaceutical Co Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in Japan, where it is headquartered. In addition to its home market, Santen Pharmaceutical Co Ltd has established a strong foothold in various regions including North America, Europe, Asia-Pacific, and Latin America. The company's commitment to expansion and growth has allowed it to serve a diverse customer base across multiple countries and regions, further strengthening its global presence and market position.

Santen Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. Founded in 1890, the company has become a global leader in ophthalmic pharmaceuticals and medical devices. Santen Pharmaceutical Co Ltd has made groundbreaking advancements in the treatment of various eye conditions, such as glaucoma, dry eye syndrome, and retinal diseases. With a strong focus on research and development, the company has introduced innovative products and technologies that improve vision and enhance patients' quality of life. Santen Pharmaceutical Co Ltd continues to expand its global presence and collaborate with leading healthcare professionals to address unmet medical needs in the field of ophthalmology.

Santen Pharmaceutical Co Ltd is a renowned Japanese company specializing in the research, development, and commercialization of ophthalmic medical products and treatments. Established in 1890, Santen Pharmaceutical has a rich history spanning over a century. The company's dedication to innovation and advanced technologies has led to numerous breakthroughs in eye care. Santen Pharmaceutical pioneers novel therapies for ocular diseases, including glaucoma, dry eye syndrome, and age-related macular degeneration. By consistently prioritizing patient needs and leveraging its scientific expertise, Santen Pharmaceutical continues to be a global leader in ophthalmic pharmaceuticals, bringing sight-saving solutions to millions worldwide.

The main competitors of Santen Pharmaceutical Co Ltd in the market include multinational pharmaceutical companies such as Novartis, Allergan, and Pfizer. These companies also specialize in developing and marketing ophthalmic pharmaceutical products, which directly compete with Santen Pharmaceutical's portfolio. Additionally, local companies like Sun Pharmaceutical Industries in India and Daiichi Sankyo in Japan may pose competition in specific regions. Santen Pharmaceutical Co Ltd continually strives to maintain a competitive edge by focusing on innovative research and development, strategic partnerships, and expanding its global presence.

Santen Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Santen Pharmaceutical Co Ltd revolves around developing and marketing innovative pharmaceutical products and medical devices for the field of ophthalmology. Santen focuses on providing solutions that address various eye diseases and conditions, including glaucoma, dry eye syndrome, and cataracts. By conducting extensive research and clinical trials, Santen aims to improve the quality of life for individuals suffering from ophthalmic disorders. Through strategic partnerships, targeted marketing, and continuous investment in research and development, Santen Pharmaceutical Co Ltd aims to position itself as a leading provider of ophthalmic treatments worldwide.

مُعامل القيمة السوقية إلى الأرباح لـ Santen Pharmaceutical Co هو ٢٥٫٣٤.

مُعامِل القيمة إلى المبيعات Santen Pharmaceutical Co هو ٢٫٢٤.

نقاط جودة AlleAktien لـ Santen Pharmaceutical Co هي 3/10.

Santen Pharmaceutical Co الإيرادات هي ٣٠١٫٩٧ مليارات JPY.

صافي الربح Santen Pharmaceutical Co هو ٢٦٫٦٣ مليارات JPY.

Santen Pharmaceutical Co Ltd is one of the leading Japanese companies in the production and marketing of pharmaceutical products. Its business activities include various segments, including research, development, manufacturing, and marketing of medications, medical devices, and cosmetic products. The company specializes in the development and manufacturing of eye preparations, particularly medications for the treatment of diseases such as glaucoma, dry eye, allergic conjunctivitis, infectious conjunctivitis, and other eye conditions. Santen also operates in the medical devices sector, offering advanced technology such as optical coherence tomography devices for the diagnosis and management of eye diseases. In recent years, the company has expanded its business field to the cosmetics market with its beauty brand Hada Labo, offering a range of skincare products specifically designed for sensitive skin. Santen also collaborates with other pharmaceutical companies to develop new technologies and therapeutics for eye diseases and other medical indications. The company is committed to innovation and research, with research and development sites in Europe, the USA, and Asia. Santen invests significant amounts in research and development to stay innovative and bring new products to market, shaping the future of ophthalmology. In summary, Santen Pharmaceutical Co Ltd offers a wide range of products and services tailored to the needs of patients, eye doctors, cosmetic enthusiasts, and pharmaceutical partners. The company is a key player in global ophthalmology and continuously invests in innovation and research to meet the needs of its customers and partners.

يوزع Santen Pharmaceutical Co أرباحًا قدرها ٣٢٫٠٠ JPY من خلال 2 عمليات توزيع موزعة على مدار السنة.

Santen Pharmaceutical Co يوزع أرباحًا 2 مرة في السنة.

الرمز الدولي للأوراق المالية الخاص بـSanten Pharmaceutical Co هو JP3336000009.

رمز WKN لـ Santen Pharmaceutical Co هو 864318.

الرمز المُختصر لـ Santen Pharmaceutical Co هو 4536.T.

خلال آخر 12 شهراً، دفعت Santen Pharmaceutical Co توزيعات أرباح بقيمة ٣٤٫٠٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ١٫٨٥ %. ومن المتوقع أن تدفع Santen Pharmaceutical Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٣٤٫٨٧ JPY.

نسبة توزيعات الأرباح الحالية لـ Santen Pharmaceutical Co هي ١٫٨٥ %.

Santen Pharmaceutical Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر أكتوبر, أبريل, أكتوبر, أبريل.

Santen Pharmaceutical Co دفعت توزيعات الأرباح كل عام خلال الـ23 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٣٤٫٨٧ JPY. وهذا يعادل عائد توزيعات أرباح قدره ١٫٩٠ %.

Santen Pharmaceutical Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ١٧ JPY من Santen Pharmaceutical Co المُعلن عنها في ١‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت Santen Pharmaceutical Co ٣٢ JPY كأرباح أسهم.

يتم توزيع أرباح Santen Pharmaceutical Co بالعملة JPY.